Contribution of oxidative stress to AF electrograms
The invention relates generally to methods of detecting reactive oxygen species (ROS) in cardiac tissue and treatment modalities for ablating ROS-associated tissue in cardiac disease. The methods rely upon targeting ROS-associated cardiac tissue for ablation and/or gene therapy in a subject using analytical tools based upon a plurality of recorded atrial EGMs for a tissue to assess ROS content and underlying AF organization as a function of ROS blockade conditions.
1. A method of targeting a region having reactive oxygen species-associated (ROS-associated) cardiac tissue for ablation in a subject, comprising:
(a) performing at least one EGM analysis of a plurality of recorded atrial EGMs for a site in the region suspected of having ROS-associated cardiac tissue;
(b) determining one or more correlations of at least one AF EGM characteristic to a region having ROS-associated cardiac tissue from the plurality of recorded atrial EGMs for the site;
(c) determining a first outcome of executing step (b) and a second outcome of executing step (b) for the site based upon the one or more correlations of at least one AF EGM characteristic to a region having ROS-associated tissue;
wherein the first outcome triggers a first decision to avoid ablation of the analysis region and the second outcome triggers a second decision to perform ablation of the analysis region of the site,
wherein the one or more correlations of at least one AF EGM characteristic to a region suspected of having ROS-associated cardiac tissue comprises a further correlation of Ca 2+ cycling characteristics of underlying myocardium of the site.
2. The method of claim 1 , wherein step (a) comprises at least one analytical subroutine selected from the group consisting of dominant frequency analysis (DF), organizational index analysis (OI), fractional interval analysis (FI) and Shannon Entropy analysis (ShEn).
3. The method of claim 1 , wherein the subject is a patient in need of preventative treatment for stroke or congestive heart failure as a result of atrial fibrillation.
4. The method of claim 1 , further comprising acquiring the plurality of recorded atrial EGMs for the site in a region suspected of having ROS-associated cardiac tissue in real-time from a subject.
5. A method of targeting reactive oxygen species-associated (ROS-associated) cardiac tissue for ablation in a subject, comprising:
(a) performing at least one EGM analysis of a plurality of recorded atrial EGMs for a site in a region suspected of having ROS-associated cardiac tissue;
(b) assessing the plurality of EGMs before or after ROS blockade;
(c) determining a first outcome of executing step (b) and a second outcome of executing step (b) for the site based upon the one or more significant changes in EGM characteristics with ROS blockade;
wherein the first outcome triggers a first decision to avoid ablation of the analysis region and the second outcome triggers a second decision to perform ablation of the analysis region of the site,
wherein the second outcome of executing step (b) for the site based upon the one or more significant changes in EGM characteristics with ROS blockade comprises a further correlation of Ca 2+ cycling characteristics of underlying myocardium of the site.
6. The method of claim 5 , wherein step (a) comprises at least one analytical subroutine selected from the group consisting of dominant frequency analysis (DF), organizational index analysis (OI), fractional interval analysis (FI) and Shannon Entropy analysis (ShEn).
7. The method of claim 5 , wherein the first outcome consists of no significant changes in EGM characteristics with ROS blockade and the second outcome consists of at least one significant change in EGM characteristics with ROS blockade.
8. The method of claim 5 , wherein the subject is a patient in need of preventative treatment for stroke or congestive heart failure as a result of atrial fibrillation.
9. The method of claim 5 , wherein step (b) is performed with one or more analytical subroutines comprising at least one member selected from the group consisting of DF, OI, FI and ShEn.
10. The method of claim 5 , wherein the tissue comprises PLA before or after ROS blockade.
11. The method of claim 5 , further comprising acquiring the plurality of recorded atrial EGMs for a tissue in a region suspected of having (ROS-associated) cardiac tissue in real-time from a subject.